DGXHealthcare · Diagnostics & ResearchThe 17 Wall Street analysts covering Quest Diagnostics, Inc. hold a median 12-month price target of $260 — +2.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 28 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Quest Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Accruals (60): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on DGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.8% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Maintains | Overweight | $250 → $260 |
| 21 Sept 2026 | Truist Securities | Maintains | Hold | — |
| 21 Sept 2026 | Truist Securities | Maintains | Hold | $250 → $260 |
| 8 Sept 2026 | UBS | Maintains | Neutral | — |
| 8 Sept 2026 | UBS | Maintains | Neutral | $232 → $245 |
| 28 July 2026 | JP Morgan | Maintains | Neutral | $220 → $250 |
| 28 July 2026 | JP Morgan | Maintains | Neutral | — |
| 25 July 2026 | UBS | Maintains | Neutral | — |
| 24 July 2026 | Baird | Maintains | Neutral | — |
| 24 July 2026 | Baird | Maintains | Neutral | $236 → $255 |
| 24 July 2026 | Barclays | Maintains | Overweight | $230 → $250 |
| 24 July 2026 | Barclays | Maintains | Overweight | — |
| 24 July 2026 | Mizuho | Maintains | Outperform | — |
| 24 July 2026 | Mizuho | Maintains | Outperform | $235 → $260 |
| 24 July 2026 | Truist Securities | Maintains | Hold | $225 → $250 |
| 24 July 2026 | Truist Securities | Maintains | Hold | — |
| 24 July 2026 | UBS | Maintains | Neutral | $220 → $232 |
| 13 July 2026 | Baird | Maintains | Neutral | $232 → $236 |
| 13 July 2026 | Baird | Maintains | Neutral | — |
| 22 Apr 2026 | Baird | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DGX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Quest Diagnostics, Inc. returned +47.1% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 48% of US stocks
Cheaper than 27% of US stocks
Cheaper than 26% of US stocks
Higher than 53% of US stocks
Higher than 64% of US stocks
Higher than 40% of US stocks
Higher than 73% of US stocks
Higher than 69% of US stocks
Higher than 74% of US stocks
Higher than 83% of US stocks
Higher than 75% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Quest Diagnostics, Inc. has a market value of $26.7B and an enterprise value of $32.6B.
Revenue in the twelve months to 30 June 2026: $11.6B. The latest quarter grew 10.0% year on year.
Net income over the same four quarters: $1.1B, a 9.6% net margin.
Diluted earnings per share, trailing twelve months: $9.42.
Free cash flow in the twelve months to 30 June 2026: $1.3B, after $554.0M of capital spending.
Quest Diagnostics, Inc. spent $363.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 25.7×; forward P/E: 20.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.42%, paying out 26% of earnings.
Quest Diagnostics, Inc. employs 60,000 people — $193K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Quest Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Zacks Investment Research headline describes Quest Diagnostics (DGX) as a top value stock for the long term. The excerpt points readers to Zacks Style Scores as a way to identify stocks.
Why it matters — DGX watchers may note the favorable value-stock framing and the article’s reference to Zacks Style Scores.
Riverwater Partners’ Sustainable Value Strategy trailed the Russell 2500 Value Index in the third quarter of 2026. New positions included Lineage, Birkenstock, Matador Resources, KBR and ICON; InterDigital, Stevanato Group and Exelixis were its top contributors.
Why it matters — The excerpt does not mention Quest Diagnostics, so it provides no company-specific information for DGX watchers.
Quest Diagnostics was upgraded after reporting its fourth consecutive earnings beat, with Q3 revenue up 10% year over year and EPS up 28.7%, and raising full-year guidance. The headline also notes a new test for Alzheimer’s.
Why it matters — The earnings momentum, raised guidance, and test announcement are developments relevant to investors tracking DGX.
AWKO Law LLP is investigating a data breach involving unauthorized access to sensitive patient information at Quest Diagnostics. The company said it identified unauthorized activity in its Quanum Lab Services Manager on October 21, 2026.
Why it matters — The reported access to patient information and resulting investigation are relevant to DGX watchers monitoring the company’s data security and privacy matters.
Quest Diagnostics confirmed a cyberattack and data breach affecting an unspecified amount of sensitive patient information stored in its systems, in a disclosure to U.S. regulators.
Why it matters — The breach concerns sensitive patient data held by Quest Diagnostics and is relevant to watchers of the company.
The 17 Wall Street analysts covering Quest Diagnostics, Inc. have a median 12-month price target of $260, with estimates ranging from $235 to $279. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Quest Diagnostics, Inc., 9 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quest Diagnostics, Inc. 95 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Quest Diagnostics, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +2.8% from the last close, and Ticker Nerd's factor model ranks Quest Diagnostics, Inc. 95 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Quest Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $235 to $279 over the next 12 months.
Quest Diagnostics, Inc. returned +47.1% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Quest Diagnostics Incorporated is a healthcare diagnostics company that provides diagnostic testing and related information services. Quest Diagnostics supports physicians, hospitals, patients, health plans, employers, and government agencies with routine clinical testing, advanced specialty testing, anatomic pathology, and consumer-ordered testing services.
The most recent item we track (Zacks Investment Research, 27 Oct 2026): "Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term". A Zacks Investment Research headline describes Quest Diagnostics (DGX) as a top value stock for the long term. The excerpt points readers to Zacks Style Scores as a way to identify stocks.
Quest Diagnostics Incorporated is a healthcare diagnostics company that provides diagnostic testing and related information services. Quest Diagnostics supports physicians, hospitals, patients, health plans, employers, and government agencies with routine clinical testing, advanced specialty testing, anatomic pathology, and consumer-ordered testing services. Its offerings include laboratory testing for areas such as cancer, heart disease, diabetes, infectious diseases, and genetic conditions, along with services for drug and alcohol screening, risk assessment, and healthcare information technology. The company operates a broad network of laboratories and patient service centers across the United States, helping connect sample collection, analysis, and reporting within the medical care process. Quest Diagnostics Incorporated plays a central role in the healthcare market by providing data and laboratory insights that support diagnosis, treatment decisions, and ongoing health management.
CEO Mr. James E. Davis · 60,000 employees · United States · https://www.questdiagnostics.com
